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OBJECTIVES We sought to evaluate the importance of time in relation to treatment, time course and
determinants of recovery of left ventricular (LV) function in patients with acute myocardial
infarction (AMI) undergoing primary percutaneous transluminal coronary angioplasty
(PTCA).
BACKGROUND Myocardial salvage has been shown to be dependent on the time elapsed from the onset of
AMI to reperfusion.
METHODS Left ventricular function was evaluated at hospital admission, after angioplasty, at 24 h and
6 months by both echocardiography and angiography and at 1, 7, 30, 90 and 180 days by
echocardiography in 101 consecutive patients.
RESULTS Patients were allocated to three groups according to interval between symptom onset and
angioplasty: ,2 h (group A), 2 to 4 h (group B) and .4 h (group C). Patients in groups A
and B showed a progressive improvement of LV function between day 7 and day 90, which
became statistically significant at day 30 (p , 0.01). No LV function changes were noted in
group C patients. Thrombolysis In Myocardial Infarction (TIMI) flow grade ,3 at 24 h was
not associated with any significant change in LV volume and function during the six-month
follow-up period. Restenosis, when associated with TIMI flow grade 3 in the infarct-related
vessel, did not influence LV function. Flow grade ,3 of the infarct-related artery was not
associated with any improvement of cardiac events independently from the time to treatment
at the initial procedure.
CONCLUSIONS Patients undergoing primary PTCA for AMI have a good recovery of LV function if TIMI
flow grade 3 is restored within 4 h. Coronary angioplasty limits further remodeling of the LV
in patients treated after 4 h. (J Am Coll Cardiol 2001;38:464–71) © 2001 by the American
College of Cardiology
Early restoration of patency of the infarct-related artery
(IRA), either by primary percutaneous transluminal coro-
nary angioplasty (PTCA) or by thrombolysis, improves
patient survival by reducing the infarct size and preserving
left ventricular (LV) function (1–13). Most reperfusion
studies have shown a direct relationship between time to
treatment and preservation of LV function and improve-
ment of patient survival (2,9). However, some studies have
also documented a beneficial effect of late opening of the
IRA (10–13). The question arises as to whether there exists
a time limit for reperfusion therapy in patients with an
evolving acute myocardial infarction (AMI). Although it
has been shown that PTCA is effective in reducing mortal-
ity in patients with AMI, there are presently few reports to
suggest a time-dependent effect of primary PTCA on LV
function and the time course of the maximal possible
recovery of LV function.
The aims of the present study were to evaluate the
importance of the time to treatment on the recovery of LV
function and to compare it with the fate of the IRA in a
consecutive, unselected series of patients with an evolving
AMI undergoing PTCA.
METHODS
Study group. The study group included 108 consecutive
patients with AMI who underwent primary PTCA within
12 h from symptom onset and within 1 h from their arrival
in the emergency department. None of them had received
thrombolytic therapy before angioplasty. Complete angio-
graphic and echocardiographic follow-up studies were avail-
able in 101 patients, and these patients were included in the
present study. Criteria for primary angioplasty were presen-
tation within 12 h from symptom onset, electrocardio-
graphic evidence of evolving AMI (.1 mm ST segment
elevation in two or more contiguous limb leads or ST
segment elevation .2 mm in the precordial leads) and the
ability of the patient to give written, informed consent.
Angioplasty protocol. After providing written, informed
consent, the patients were transferred immediately to the
catheterization laboratory. In general, the procedure was
started within 1 h of the arrival of patient to the emergency
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room. Unless contraindicated, routine pre-medications con-
sisted of intravenous heparin (1,000 U/h), aspirin (325 mg
orally) and intravenous nitroglycerin (7 to 8 mg/kg body
weight per h). The angiographic protocol was started with
left ventriculography, followed by coronary angiography.
Coronary angioplasty was performed only on the IRA.
Intravenous heparin was continued (1,000 U/h) for at least
24 h after the procedure. Procedural success was defined as
residual stenosis ,30%, without major complications (death
or urgent coronary artery bypass graft surgery). All patients
underwent an angiographic control study within 36 h.
Heparin was then stopped, and the sheaths were removed
when the activated clotting time dropped ,160 s. All
patients were maintained on aspirin (325 mg/day) and
beta-blockers, calcium antagonists and oral nitrates, either
alone or in combination, together with angiotensin-
converting enzyme inhibitors. Cardiac enzymes were ob-
tained every 8 h for at least 48 h after angioplasty. Before
hospital discharge, echocardiography was performed. Pa-
tients with worsening angina, reinfarction or other cardiac
events before discharge underwent repeat catheterization.
Evaluation of LV function. Left ventriculography was
performed (in the 30° right anterior oblique orthogonal
projection) before coronary angiography, after PTCA, and
was repeated at 24 h and 6 months after PTCA. Left
ventricular volumes were calculated by the area–length
method. Echocardiography was performed at hospital ad-
mission, soon after PTCA and at 1, 7, 30, 90 and 180 days
after PTCA, using a phased-array electronic ultrasound
system (Sonos 2500, Hewlett-Packard, Andover, Massa-
chusetts). Images were recorded on VHS videotape, and
end-diastolic and end-systolic frames were selected from
three standard apical views. Volumes were calculated by the
biplane area–length method. The LV was divided into 16
segments (14). For each segment, systolic wall motion and
thickening were visually graded with the following semi-
quantitative scoring system: 1 5 normal or hyperkinesia;
2 5 hypokinesia; 3 5 akinesia; and 4 5 dyskinesia. Left
ventricular wall motion score index (WMSI) was derived
using the sum of the individual scores divided by the total
number of analyzed segments. Experienced investigators,
who had no knowledge of the clinical and angiographic
data, analyzed the left ventriculograms and echocardio-
grams.
Follow-up. All patients underwent a six-month angio-
graphic control study. Patients with evidence of recurrent
ischemia underwent repeat cardiac catheterization, followed
by a new revascularization procedure (mechanical or surgi-
cal) if needed. The mean period of follow-up was 32.7 6
13.3 months. All patients underwent echocardiography at
each follow-up visit.
Statistical analysis. Data are presented as the mean
value 6 SD or as percentages where appropriate. Baseline
clinical differences were analyzed using the unpaired the t
test. To compare proportions, either the chi-square test or,
when appropriate, the Fischer exact test was used. Two-way
(time-group) repeated measures analysis of variance
(ANOVA) was used to test differences between the groups
for the evolution, across time, of continuous variables. The
data for which ANOVA was used are presented in each case
as follows: p value for treatment by period interaction effect;
p value for treatment effect; and p value for period effect.
Linear regression analysis was performed to evaluate the
relationship between LV ejection fraction and cardiac en-
zyme release. A p value ,0.05 was considered significant.
Statistical analysis was performed using the Statview 4.5
software program (SAS Institute, Cary, North Carolina).
RESULTS
The baseline clinical and angiographic characteristics of
patients are described in Tables 1 and 2. The patients were
allocated to three groups according to the time between
symptom onset and primary PTCA: ,2 h (n 5 24, group
A); 2 to 4 h (n 5 32, group B); and .4 h (n 5 45, group
C). The three groups were comparable in terms of clinical
characteristics and the use of cardiac medications during and
after the procedure. The procedural success rate was 100%.
The majority of patients from group C (n 5 32, 71%) were
reperfused within 6 h from symptom onset. Patients from
the three groups had comparable clinical and angiographic
characteristics and infarct size.
Cardiac enzymes. Peak levels of cardiac enzymes were
comparable in all three groups. However, the time to peak
cardiac enzymes release was significantly higher in group C
than in groups A and B (16 6 3 vs. 7 6 5 and 9 6 4 h,
respectively, p , 0.001) (Fig. 1).
No major complications occurred during the procedure or
during the hospital period in any patient. During the
hospital period, one patient from group B had recurrence of
angina and underwent repeat PTCA. Three patients (one
from each group) had minor bleeding not requiring blood
transfusion.
Left ventricular function. Pre-procedural LV volumes and
ejection fractions, as well as WMSI, were comparable in the
three groups. After the procedure, the patients in groups A
and B showed a significant and progressive reduction in LV
volume (Fig. 2) and progressive improvement of LV ejec-
tion fraction between day 1 and day 180 (0.42 6 0.04 vs.
0.43 6 0.03; ANOVA: p , 0.0001 for treatment by period
Abbreviations and Acronyms
AMI 5 acute myocardial infarction
ANOVA 5 analysis of variance
CK 5 creatine kinase
IRA 5 infarct-related artery
LV 5 left ventricular
PTCA 5 percutaneous transluminal coronary
angioplasty
TIMI 5 Thrombolysis In Myocardial Infarction
WMSI 5 wall motion score index
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interaction effect, p , 0.0073 for treatment effect and p ,
0.0001 for period effect), whereas no significant difference in
LV function was noted during the first seven days (0.42 6
0.02 and 0.43 6 0.03 vs. 0.44 6 0.03 and 0.45 6 0.04, p 5
NS for groups A and B at day 1 vs. day 7) and between three
and six months (0.51 6 0.04 and 0.52 6 0.03 vs. 0.52 6
0.04 and 0.51 6 0.04, p 5 NS for groups A and B at 3 vs.
6 months) (Fig. 3). A significant decrease in WMSI was
noted in these two groups of patients (ANOVA for group
A: p , 0.0001 for treatment by period interaction effect,
p , 0.0081 for treatment effect and p , 0.0001 for period
effect; ANOVA for group B: p , 0.0001 for treatment by
period interaction effect, p , 0.0084 for treatment effect
and p , 0.0001 for period effect) (Fig. 4).
No difference in improvement of LV function and re-
gional wall motion abnormalities was found according to
the location of the IRA. In these patients, no significant
relationship was found between the degree of LV function
Table 1. Baseline Clinical Characteristics
Group A
(n 5 24)
Group B
(n 5 32)
Group C
(n 5 45)
Total
(n 5 101)
Age (years) 58 6 9 59 6 10 56 6 7 58 6 8
Males 73% 68% 70% 71%
Previous MI 0 0 0 0
Risk factors
Hypertension 16 (67%) 20 (65%) 28 (62%) 66 (65%)
Hypercholesterolemia 11 (46%) 14 (43%) 21 (47%) 46 (45%)
Smoking 14 (58%) 17 (53%) 24 (53%) 55 (54%)
Diabetes mellitus 6 (25%) 7 (22%) 11 (24%) 24 (24%)
Preinfarct angina 7 (29%) 10 (31%) 13 (29%) 30 (30%)
Infarct location
Anterior 14 (58%) 19 (59%) 25 (56%) 57 (56%)
Inferior 7 (29%) 8 (25%) 13 (29%) 28 (28%)
Lateral 3 (13%) 5 (16%) 7 (16%) 16 (16%)
Peak CK-MB (ng/ml) 318 6 15 312 6 20 335 6 33 321 6 20
Time to peak CK-MB (ng/ml) 7 6 2 9 6 3 16 6 4*
*p , 0.001 for group C vs. groups A and B. Data are presented as the mean value 6 SD or number (%) of patients.
CK-MB 5 creatine kinase-MB fraction; MI 5 myocardial infarction.
Table 2. Baseline and Angiographic Characteristics
Group A
(n 5 24)
Group B
(n 5 32)
Group C
(n 5 45)
Total
(n 5 101)
Extension of CAD
One-vessel disease 13 (54%) 18 (56%) 25 (55%) 56 (55%)
Two-vessel disease 7 (29%) 9 (28%) 12 (27%) 28 (28%)
Three-vessel disease 4 (17%) 5 (16%) 8 (18%) 17 (17%)
IRA
LAD 14 (58%) 19 (55%) 25 (56%) 58 (57%)
LCx 3 (13%) 5 (16%) 6 (13%) 14 (14%)
RCA 7 (29%) 8 (25%) 13 (29%) 28 (28%)
RVD of IRA (mm) 3.4 6 0.4 3.3 6 0.5 3.4 6 0.3 3.4 6 0.5
Collateral vessels to IRA 3 (13%) 4 (13%) 6 (13%) 13 (13%)
LVEF 0.41 6 0.08 0.39 6 0.06 0.40 6 0.05 0.40 6 0.07
After procedure
IRA—DS (%) 28 6 5 24 6 6 26 6 8 26 6 7
IRA—MLD (mm) 3.1 6 0.4 2.96 6 0.3 3.09 6 0.3 3.02 6 0.3
TIMI flow grade
0 0 0 0 0
1 1 (3.1%) 1 (2.2%) 2 (2%)
2 1 (4.5%) 3 (9.3%) 6 (13.3%) 10 (9.9%)
3 23 (95.5%) 28 (87.6%) 38 (84.5%) 89 (88.1%)
24-h angiography
TIMI flow grade
0 0 0 0 0
1 0 0 0 0
2 4 (12.5%) 7 (15.5%) 11 (11%)
3 24 (100%) 28 (87.5%) 38 (84.5%) 89 (89%)
Data are presented as the mean value 6 SD or number (%) of patients.
CAD 5 coronary artery disease; DS 5 diameter stenosis; IRA 5 infarct-related artery; LAD 5 left anterior descending
coronary artery; LCx 5 left circumflex coronary artery; LVEF 5 left ventricular ejection fraction; MLD 5 minimal lumen
daimeter; RCA 5 right coronary artery; RVD 5 reference vessel diameter; TIMI 5 Thrombolysis In Myocardial Infarction.
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recovery and cardiac enzymes release (Fig. 2), nor between
cardiac enzymes release and increase in ejection fraction
(r 5 0.20, p 5 NS).
Patency of the IRA and LV function. Post-procedural
slow flow (TIMI flow grade ,3) occurred in 12 patients.
This phenomenon was more frequently observed in patients
treated after 2 h from symptom onset (1 patient from group
A vs. 11 patients from groups B and C, p , 0.001). At the
24-h angiographic control study, the patients’ slow flow was
still present in all 11 patients from groups B (n 5 4) and C
(n 5 7) (Table 3). Improvement of LV function at
follow-up was not present in any patient showing slow flow
at 24 h independently from the time to treatment (Table 4).
Angiographic restenosis was noted in 32 patients (32%)
at the six-month follow-up. The incidence of restenosis was
comparable between the three groups: 8 patients (33%) from
Figure 1. Peak and time to peak creatine kinase (CK) and CK-MB levels in the three study groups after reperfusion. ,p , 0.001.
Figure 2. Changes in left ventricular diastolic and systolic volumes in all study groups during the follow-up period.
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group A; 10 patients (31%) from group B; and 14 patients
(32%) from group C (Table 5). Restenosis had no impact on
recovery of LV function, unless it resulted in TIMI flow
grade ,3 in the IRA (Tables 5 and 6). Individual analysis of
LV function and clinical follow-up of the 17 patients who
had restenosis associated with TIMI flow grade ,3 in the
treated vessel showed no improvement of LV function and
volume in these patients, independently from the time to
treatment. Clinical events, including death and congestive
heart failure during long-term-follow-up, were more fre-
quent in patients who had total reocclusion or TIMI flow
grade 1 in the IRA, independently from the time to
treatment (Table 6).
At a mean follow-up duration of 32.7 6 13.3 months, the
target lesion revascularization rate, as well as mortality, were
similar in all three groups. Cardiac death occurred in three
patients (2.9%). All three patients had a total reocclusion of
the IRA at six-month angiographic follow-up.
DISCUSSION
The present study shows that primary PTCA for patients
with AMI is effective in improving LV function if per-
formed within 4 h from symptom onset. Nevertheless, even
late recanalization, after 4 h, of the IRA appears effective in
preventing LV enlargement and remodeling. Our data show
that very early reperfusion (,2 h) with primary PTCA was
associated with low early and in-hospital, as well as long-
term follow-up, clinical events. Patients who were reper-
fused within 4 h show similar results. Also, LV function
recovery, monitored during follow-up, was similar in pa-
tients treated within 4 h from symptom onset. Interestingly,
improvement of LV function variables became apparent
only seven days after the procedure, reaching statistical
significance at 30 days and progressively continuing until
the third month after reperfusion. No further significant
improvement was observed beyond this time. In patients
Figure 3. Changes in left ventricular ejection fraction in all study groups during the follow-up period.
Figure 4. Changes in wall motion score index in all study groups during the follow-up period. ,p , 0.01; ,,p , 0.001.
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reperfused after 4 h, no significant LV function changes
were observed during follow-up (Table 3, Fig. 2, 3 and 4).
However, as shown in Figures 2, 3 and 4,, these variables
did not worsen during follow-up, indicating that the ex-
pected post-infarction remodeling did not occur in group C.
Our data also show that there were no differences in peak
levels of cardiac enzymes among the three groups, although
the time to peak cardiac enzymes was significantly longer in
patients reperfused late, as compared with those reperfused
early (Fig. 1). Restenosis affected the recovery of LV
function only when flow in the IRA was ,3 (TIMI grade),
and this relationship was independent of the time to
treatment (Table 6). However, the limited number of these
patients did not allow statistical analysis.
Beneficial effect of late recanalization: potential mecha-
nisms. The “open-artery” hypothesis is based on the ob-
servation that those hearts in which experimental coronary
ligation is released develop less ventricular dilation than
those in whose occlusion is maintained (15). Indeed, be-
cause LV dilation after myocardial infarction can be caused
by lengthening of viable adjacent segments (16), a patent
IRA may limit remodeling by enabling earlier formation of
a firmer myocardial scar (17). Avoidance of unfavorable LV
morphology results in many secondary, later benefits, such
as a reduction of wall stress, prevention of volume overload,
hypertrophy and improvement of ejection fraction. Indeed,
in our study, even though patients revascularized after 4 h
did not show any significant myocardial salvage, they also
did not exhibit a trend toward progressive deterioration of
LV function, as this is usually observed in post-infarction
patients in whom the IRA remains occluded (18,19). Our
results are in keeping with those of a recent study addressing
the influence of an additional treatment delay inherent in
the transfer of patients with AMI, who where first admitted
to hospitals without invasive facilities, to a tertiary-care
referral center for primary PTCA (20). In that study, the
additional delay (albeit, all patients were reperfused within
6 h) had a deleterious effect on myocardial salvage, as
reflected by a larger infarct size and a lower ejection fraction;
however, the six-month clinical outcome was not affected.
Clinical implications. The traditional paradigm in reper-
fusion therapy is that early reperfusion results in myocardial
salvage and improved survival. The term “early” is not well
defined. Previous studies have suggested that a significant
amount of myocardium can be salvaged if recanalization is
achieved within 2 h (1,10,21–23). In the present study, we
found that myocardial salvage could also be achieved in
patients reperfused within 4 h with primary PTCA. Indeed,
in the majority of patients with AMI undergoing primary
PTCA, reperfusion is effectively achieved within this time
lag. It is important to note that in our patients, late PTCA
(.4 h) was not associated with LV remodeling. Because
Table 3. Six-Month Follow-Up of Left Ventricular Ejection Fraction in Patients With TIMI Flow Grade ,3 at 24-h Angiography
Pt.
No. Group
Baseline Six-Month Control Study
TIMI
Flow
Grade
EDVI
(ml/m2)
ESVI
(ml/m2)
EF
(%)
WMSI
(ml/m2)
TIMI
Flow
Grade
EDVI
(ml/m2)
ESVI
(ml/m2)
EF
(%) WMSI
1 B 2 82 50 39 2.47 2 78 47 40 2.31
2 B 2 77 45 42 2.36 1 79 46 42 2.34
3 B 2 78 47 40 2.39 2 80 48 40 2.37
4 B 2 81 51 37 2.43 1 83 52 37 2.44
5 C 2 84 53 37 2.46 1 82 50 39 2.45
6 C 2 87 55 37 2.49 2 85 51 40 2.43
7 C 2 83 49 41 2.39 2 78 45 42 2.37
8 C 2 79 46 42 2.45 3 81 47 42 2.43
9 C 2 88 51 42 2.48 0 85 48 44 2.40
10 C 2 91 57 37 2.51 0 89 57 36 2.49
11 C 2 82 55 33 2.63 0 90 61 32 2.65
EDVI 5 end-diastolic volume index; EF 5 ejection fraction; ESVI 5 end-systolic volume index; TIMI 5 Thrombolysis In Myocardial Infarction; WMSI 5 wall motion score
index.
Table 4. Angiographic Follow-Up (Six Months)
Group A
(n 5 24)
Group B
(n 5 32)
Group C
(n 5 45)
All Patients
(n 5 101)
Angiographic restenosis 8 (33%) 10 (31%) 14 (32%) 32 (32%)
TIMI flow grade in IRA
3 20 (85%) 26 (81%) 38 (84%) 84 (82%)
2 2 2 3 7
1 1 2 1 4
Total re-occlusion 1 (4.4%) 2 (6.2%) 3 (6.6%) 6 (6%)
LVEF 0.54 6 0.08 0.50 6 0.06 0.43 6 0.03 0.49 6 0.05
Mean gain in EF 0.13 0.09 0.03 0.08
Data are presented as the number (%) of patients or mean value 6 SD.
IRA 5 infarct-related artery; LVEF 5 left ventricular ejection fraction; TIMI 5 Thrombolysis In Myocardial Infarction.
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these data support the open-IRA hypothesis, our proposal is
to increase the window period for effective reperfusion to
4 h. An open IRA, even if too late for myocardial salvage,
may prevent ventricular dilation and promote electrical
stability, resulting in survival benefit (11,15–20,24).
A second implication of this study relates to the time
course of LV function recovery after early reperfusion:
immediate or in-hospital improvements of LV function are
not to be expected, because significant changes occur only
30 days after reperfusion. This is probably related to
myocardial stunning (25,26). In a previous study, we were
able to demonstrate the efficacy of calcium antagonists
against post-ischemic stunning in patients with AMI (27).
Early recovery of LV function in patients with ischemic LV
dysfunction can reduce 30-day mortality and cardiac events.
Another implication of this study relates to the signifi-
cance of peak creatine kinase (CK) and CK-MB levels as
reliable markers for infarct size. In the present study, the
peak level of cardiac enzymes was not a predictor of infarct
size and LV damage. Rather, the time to peak level
correlated with the time to reperfusion, with early peaking
occurring in patients who were reperfused early (,4 h).
Early peaking of CK results from the abrupt washout of the
previously occluded artery and its related vasculature (28–
30). Improvement of LV function was independent of the
total amount of CK released after reperfusion.
Finally, late restenosis in patients undergoing primary
PTCA does not influence recovery of LV function at
long-term follow-up, as long as TIMI flow grade 3 is
preserved in the IRA. Consequently, the flow grade in the
IRA, rather than restenosis, seems to be a better predictor of
LV function recovery and survival benefit after primary
PTCA.
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Table 5. Follow-Up in Patients With Angiographic Restenosis and TIMI Flow Grade ,3
Pt.
No. Group
Baseline Six-Month Follow-Up
TIMI
EDVI
(ml/m2)
ESVI
(ml/m2)
EF
(%) WMSI
EDVI
(ml/m2)
ESVI
(ml/m2)
EF
(%) WMSI Events
1 A 2 78 44 44 2.34 76 42 45 2.29 90% Restenosis, re-PTCA
2 A 2 76 42 45 2.31 73 40 45 2.35 80% Restenosis, re-PTCA
3 A 1 82 49 40 2.43 84 51 39 2.46 90% Restenosis, re-PTCA
4 A 0 77 46 41 2.39 80 49 39 2.44 100% Reocclusion, no events
5 B 2 82 50 39 2.47 78 47 40 2.31 90% Restenosis, angina
6 B 2 78 47 40 2.39 80 48 40 2.37 80% Restenosis, re-PTCA
7 B 1 77 45 42 2.36 79 46 42 2.34 90% Restenosis, CABG
8 B 1 80 48 40 2.43 78 46 42 2.38 90% Restenosis, CABG
9 B 0 75 42 44 2.34 83 52 37 2.44 100% Reocclusion, death
10 B 0 81 50 38 2.57 84 53 37 2.58 100% Reocclusion, CABG
11 C 2 83 48 42 2.46 81 49 40 2.47 95% Restenosis, CABG
12 C 2 87 55 37 2.49 85 51 40 2.43 90% Restenosis, re-PTCA
13 C 2 83 49 41 2.39 78 45 42 2.37 90% Restenosis, re-PTCA
14 C 1 84 53 37 2.46 82 50 39 2.45 90% Restenosis, death
15 C 0 88 51 42 2.48 85 48 44 2.40 100% Reocclusion, CHF
16 C 0 91 57 37 2.51 89 57 36 2.49 100% Reocclusion, CHF
17 C 0 82 55 33 2.63 90 61 32 2.65 100% Reocclusion, death
CABG 5 coronary artery bypass graft surgery; CHF 5 cardiac heart failure; PTCA 5 percutaneous transluminal coronary angioplasty; other abbreviations as in Table 3.
Table 6. Long-Term Clinical Follow-Up
Group A
(n 5 24)
Group B
(n 5 32)
Group C
(n 5 45)
Total
(n 5 101)
Death 1 (4.1%) 1 (3.1%) 2 (4.4%) 4 (3.9%)
Cardiac 1 (4.1%) 0 2 (4.4%) 3 (2.9%)
Noncardiac 0 1 (3.1%) 0 1 (0.9%)
Recurrent ischemia 8 (33.3%) 10 (31.1%) 15 (33.3%) 33 (32.6%)
HF 0 0 2 (4.4%) 2 (1.9%)
Reinfarction 0 1 (3.1%) 2 (4.4%) 3 (2.9%)
Repeat PTCA 6 (25%) 7 (21.9%) 9 (20%) 22 (21%)
CABG 2 (8.3%) 3 (9.3%) 4 (8%) 10 (9.9%)
Total TLR rate 8 (33.3%) 10 (31.2%) 13 (29.7%) 31 (31%)
Event-free survival 15 (62.6%) 21 (65.7%) 26 (61.5%) 62 (61.9%)
Data are presented as the number (%) of patients.
CABG 5 coronary artery bypass graft surgery; HF 5 heart failure; PTCA 5 percutaneous transluminal coronary angioplasty;
TLR 5 target lesion revascularization.
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